Literature DB >> 11924898

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.

Biljana Georgievska1, Deniz Kirik, Carl Rosenblad, Cecilia Lundberg, Anders Björklund.   

Abstract

We used a recombinant lentiviral vector (rLV) for gene delivery of GDNF to the striatum, and assessed its neuroprotective effects in the intrastriatal 6-hydroxydopamine (6-OHDA) lesion model. The level of GDNF expression obtained with the rLV-GDNF vector was dose-related and ranged between 0.9-9.3 ng/mg tissue in the transduced striatum, as determined by ELISA, and 0.2-3.0 ng/mg tissue were detected in the ipsilateral substantia nigra (SN), due to anterograde transport of the GDNF protein. GDNF expression was apparent at 4 days and maintained for > 8 months after injection. Striatal delivery of rLV-GDNF efficiently protected the nigral dopamine (DA) neurons and their projection, against the 6-OHDA lesion (65-77% of intact side). Sprouting of the lesioned axons was observed along the nigrostriatal pathway, precisely corresponding to the areas containing anterogradely transported GDNF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11924898     DOI: 10.1097/00001756-200201210-00019

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  25 in total

Review 1.  Anterograde transport of neurotrophic factors: possible therapeutic implications.

Authors:  Matteo Caleo; Maria Cristina Cenni
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

Review 2.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

3.  Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor.

Authors:  A M Fletcher; T H Kowalczyk; L Padegimas; M J Cooper; D M Yurek
Journal:  Neuroscience       Date:  2011-08-04       Impact factor: 3.590

Review 4.  Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review.

Authors:  Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2007-01-04       Impact factor: 4.130

5.  Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.

Authors:  Luis Quintino; Giuseppe Manfré; Erika Elgstrand Wettergren; Angrit Namislo; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther       Date:  2013-07-24       Impact factor: 11.454

Review 6.  Trophic factors therapy in Parkinson's disease.

Authors:  Shilpa Ramaswamy; Katherine E Soderstrom; Jeffrey H Kordower
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

Review 7.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

Review 8.  Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.

Authors:  Dao Pan
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

Review 9.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats.

Authors:  Melissa K McCoy; Kelly A Ruhn; Terina N Martinez; Fiona E McAlpine; Armin Blesch; Malú G Tansey
Journal:  Mol Ther       Date:  2008-07-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.